医学
心脏移植
重症监护医学
心力衰竭
免疫抑制
目的地治疗
人工心脏
移植的桥梁
移植
金标准(测试)
内科学
心脏病学
作者
Karl Bounader,Erwan Flécher
出处
期刊:Presse Medicale
[Elsevier]
日期:2023-10-27
卷期号:53 (1): 104191-104191
被引量:5
标识
DOI:10.1016/j.lpm.2023.104191
摘要
In the last decades, outcomes significantly improved for both heart transplantation and LVAD. Heart transplantation remains the gold standard for the treatment of end stage heart failure and will remain for many years to come. The most relevant limitations are the lack of grafts and the effects of long-term immunosuppressive therapy that involve infectious, cancerous and metabolic complications despite advances in immunosuppression management. Mechanical circulatory support has an irreplaceable role in the treatment of end-staged heart failure, as bridge to transplant or as definitive implantation in non-transplant candidates. Although clinical results do not overcome those of HTx, improvement in the new generation of devices may help to reach the equipoise between the two therapies. This review will go through the evolution, current status and perspectives of both therapeutics.
科研通智能强力驱动
Strongly Powered by AbleSci AI